论文部分内容阅读
目的对92例分化型甲状腺癌术后131I治疗的临床效果进行分析。方法 92例分化型甲状腺癌患者术后行131I清甲治疗,剂量为50～150 m Ci,25例未发现转移患者治疗1～2次后定期随访,61例有远处转移患者长期阶段性治疗,每次给予150～200 mC i,每次治疗间隔6个月,少数病例间隔6～12个月,治疗中6例失随访,11例因病灶不摄取131I放弃治疗或病情恶化、死亡。合并转移患者治疗疗效判断:①治愈;②好转或稳定;③无效或恶化。患者随访期1～9年。结果 92例DTC患者清甲治疗后一次清甲完全者75例(87.2%),61例转移患者治疗后治愈者14例(23.0%),好转36例(59.0%),11例治疗无效。治疗期间未见严重毒副作用。结论分化型甲状腺癌患者术后131I治疗能够有效降低复发和转移,对于合并转移患者疗效较为满意,同时应加强宣传,提倡合理规范手术,提高DTC患者术后131I治疗比例。
Objective To analyze the clinical effect of 131I treatment in 92 cases of differentiated thyroid carcinoma after operation. Methods Ninety-two patients with differentiated thyroid cancer underwent 131I treatment at a dose of 50-150 mCi. Twenty-five patients with metastatic thyroid cancer were followed up regularly for one to two times. Totally 61 patients with distant metastasis were treated with long-term stage treatment , Each given 150 ~ 200 mCi, each treatment interval of 6 months, a few cases interval of 6 to 12 months, 6 cases of follow-up treatment was missed, 11 cases of 131I did not give up because of lesions or treatment of exacerbations, death. Treatment of patients with combined metastasis judgment: ① cure; ② improve or stable; ③ invalid or worse. Patients were followed up for 1 to 9 years. Results In 92 DTC patients, 75 cases (87.2%) of meningitis were completely metered after mecca treatment, 14 cases (23.0%) were cured and 36 cases (59.0%) were cured in 61 cases, and 11 cases were ineffective. No serious side effects during treatment. Conclusions 131I treatment of patients with differentiated thyroid cancer can effectively reduce the recurrence and metastasis, and is satisfactory for the treatment of patients with metastatic thyroid carcinoma. At the same time, it is necessary to strengthen publicity to promote rational operation and improve the proportion of 131I after DTC.